RTW Investments LP Makes New Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

RTW Investments LP bought a new stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 11,764,000 shares of the company's stock, valued at approximately $18,587,000. RTW Investments LP owned 33.65% of RAPT Therapeutics as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in RAPT. Redmile Group LLC boosted its holdings in RAPT Therapeutics by 1,183.4% in the fourth quarter. Redmile Group LLC now owns 6,475,317 shares of the company's stock valued at $10,231,000 after purchasing an additional 5,970,785 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of RAPT Therapeutics by 50.5% during the 4th quarter. Nuveen Asset Management LLC now owns 116,925 shares of the company's stock valued at $185,000 after buying an additional 39,216 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of RAPT Therapeutics during the 4th quarter valued at approximately $63,000. Orbimed Advisors LLC acquired a new stake in shares of RAPT Therapeutics during the fourth quarter worth approximately $20,754,000. Finally, Deep Track Capital LP bought a new stake in shares of RAPT Therapeutics in the fourth quarter worth $9,498,000. 99.09% of the stock is owned by institutional investors and hedge funds.

RAPT Therapeutics Stock Down 7.0%

NASDAQ:RAPT traded down $0.07 during trading hours on Wednesday, reaching $0.90. 286,479 shares of the stock were exchanged, compared to its average volume of 1,259,138. The stock has a market capitalization of $118.53 million, a P/E ratio of -0.33 and a beta of -0.04. The firm has a 50 day simple moving average of $0.99 and a 200-day simple moving average of $1.20. RAPT Therapeutics, Inc. has a 52 week low of $0.71 and a 52 week high of $4.83.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.23. As a group, analysts expect that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of RAPT Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $4.00.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.